CereVance completed enrollment in its pivotal Phase 3 ARISE trial of solengepras in Parkinson’s disease and closed an oversubscribed $20 million Series C financing.
The randomized, double-blind, placebo-controlled ARISE study enrolled 341 patients across the United States, Europe, United Kingdom and Australia, enrolling adults age 30 and older with motor fluctuations and an average of three or more hours of total OFF time per day.
Study participants were randomized to solengepras 75 mg, 150 mg or placebo once daily for 12 weeks; the primary endpoint is change from baseline to week 12 in average daily OFF time for the 150 mg dose versus placebo. The company expects topline data at the end of third quarter 2026.
The Series C round was led by existing investors and included participation from Double Point Ventures, Gates Frontier, Google Ventures, Lightstone Ventures, MQB Partners, SV Health Investors’ Dementia Discovery Fund and UPMC, and proceeds are expected to fund operations through mid-2027.
Solengepras is a once-daily, non-dopaminergic GPR6 inhibitor designed to reduce OFF periods while avoiding dopaminergic side effects.
